Biogen Idec Inc (BIIB) 299.29 $BIIB
Repros Gets Additional FDA Guidance for Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 4:20PM CDT
Repros Therapeutics Inc. (RPRX) announced that it has received additional guidance from the FDA related to its secondary hypogonadism candidate, Androxal.
Lannett Shares Down on Subpoena Receipt from Connecticut AG - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 4:10PM CDT
Lannett Company (LCI) has received a subpeona from Connecticut AG.
CVS Caremark Forms Clinical Alliances to Boost Health Care - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 2:20PM CDT
Per the terms of the collaborations, CVS Caremark (CVS) will offer critical prescription and visit information to these healthcare providers through the secured electronic medical record (EMR) systems.
Baxter Q2 Earnings Beat Estimates, But Guidance Soft
at Investor's Business Daily - Thu Jul 17, 11:29AM CDT
Medical-product maker Baxter International (BAX) beat analysts' Q2 expectations Thursday, but its conservative guidance underwhelmed the Street. Shares dropped early but recovered and was flat in midday trading in the stock market today. Baxter's Q2...
Technical Update, Leadership Appointments, Therapy Approvals, Notifications, and Clinical Trial Results - Analyst Notes on Biogen, Medivation, BioMarin, Acorda and Targacept
PR Newswire - Thu Jul 17, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Medivation, Inc. (NASDAQ: MDVN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Acorda Therapeutics, Inc. (NASDAQ: ACOR) and Targacept, Inc. (NASDAQ: TRGT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4882-100free.
Ligand Pharmaceuticals (LGND) in Focus: Stock Falls 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:31AM CDT
Ligand Pharmaceuticals has seen flat earnings estimate revisions for the current year along with a significant decline in its share price for the past month
Why Express Scripts Inc., Monster Beverage Corporation, and Biogen Idec Inc. Are Today's 3 Worst Sto
John Divine, The Motley Fool - Motley Fool - Wed Jul 16, 6:45PM CDT
Seven of the stock market's 10 sectors finished higher today, as a second day of testimony from Federal Reserve Chairwoman Janet Yellen served to assure investors that interest rates will remain low indefinitely. With that in mind, stocks seem to be...
Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 3:30PM CDT
The U.S. Patent and Trademark Office issued a new patent to Arena Pharmaceuticals, Inc. (ARNA) for its pain candidate APD371.
Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS)
Business Wire - Wed Jul 16, 7:01AM CDT
Biogen Idec (NASDAQ:BIIB) announced today a new program with Yahoo Health to raise awareness of innovative efforts to help people with multiple sclerosis (MS) across the country. The MS Visionaries(TM) program showcases self-starters who have developed programs, tools or services to benefit the MS community. Profiles of these individuals are now featured on Yahoo Health, a new digital magazine covering modern health and wellness topics.
Hospira Upgraded to Strong Buy on Orchid Facility Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 4:00PM CDT
On Jul 12, Zacks Investment Research upgraded Hospira Inc. (HSP) to a Zacks #1 Rank (Strong Buy).
Biogen Idec Falls 2.42% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 15, 3:52PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $311.92 to a high of $321.81. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $315.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 2.42%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jul 15, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $311.92 to a high of $321.81. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $315.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CVS Caremark to Expand with Navarro Discount Pharmacy Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 2:10PM CDT
Post-acquisition, CVS Caremark (CVS) will own Navarro's 33 retail drugstore locations and a specialty pharmacy named Navarro Health Services.
Will Abbott Laboratories (ABT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 11:40AM CDT
Abbott Labs (ABT) has a Zacks Rank #3 with an Earnings ESP of 0.00%.
Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 10:00AM CDT
Peregrine Pharmaceuticals, Inc. (PPHM) reported a net loss of 6 cents per share in the fourth quarter of fiscal 2014.
Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 8:04AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise 23% on the day.
IBD Big Cap 20 Leaders Hold Up Well Despite Shaky Market
at Investor's Business Daily - Mon Jul 14, 5:56PM CDT
A rising distribution day count in the major averages and an uptrend under pressure might lead some to believe that the market is in trouble -- poised for some sort of pullback. Not so fast. The charts of many IBD Big Cap 20 names don't reflect a...
Sunesis' Pediatric Plan Accepted in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 5:45PM CDT
Sunesis Pharmaceuticals, Inc.'s (SNSS) Pediatric Investigation Plan for Qinprezo was accepted by the EMA???s Pediatric Committee for AML.
Will Johnson & Johnson (JNJ) Beat this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 3:45PM CDT
Johnson & Johnson (JNJ) is scheduled to report second quarter 2014 results before the opening bell on Jul 15.
Bruker's Inspire Mapping System Fails to Inspire Share Prices - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 2:20PM CDT
Bruker Corporation's (BRKR) Inspire is a self-optimizing pioneering scanning system that delivers 10-nanometer spatial resolution in chemical and materials property mapping.
Repros Gets Additional FDA Guidance for Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 4:20PM CDT
Repros Therapeutics Inc. (RPRX) announced that it has received additional guidance from the FDA related to its secondary hypogonadism candidate, Androxal.
Lannett Shares Down on Subpoena Receipt from Connecticut AG - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 4:10PM CDT
Lannett Company (LCI) has received a subpeona from Connecticut AG.
CVS Caremark Forms Clinical Alliances to Boost Health Care - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 2:20PM CDT
Per the terms of the collaborations, CVS Caremark (CVS) will offer critical prescription and visit information to these healthcare providers through the secured electronic medical record (EMR) systems.
Baxter Q2 Earnings Beat Estimates, But Guidance Soft
at Investor's Business Daily - Thu Jul 17, 11:29AM CDT
Medical-product maker Baxter International (BAX) beat analysts' Q2 expectations Thursday, but its conservative guidance underwhelmed the Street. Shares dropped early but recovered and was flat in midday trading in the stock market today. Baxter's Q2...
Technical Update, Leadership Appointments, Therapy Approvals, Notifications, and Clinical Trial Results - Analyst Notes on Biogen, Medivation, BioMarin, Acorda and Targacept
PR Newswire - Thu Jul 17, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Medivation, Inc. (NASDAQ: MDVN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Acorda Therapeutics, Inc. (NASDAQ: ACOR) and Targacept, Inc. (NASDAQ: TRGT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4882-100free.
Ligand Pharmaceuticals (LGND) in Focus: Stock Falls 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:31AM CDT
Ligand Pharmaceuticals has seen flat earnings estimate revisions for the current year along with a significant decline in its share price for the past month
Why Express Scripts Inc., Monster Beverage Corporation, and Biogen Idec Inc. Are Today's 3 Worst Sto
John Divine, The Motley Fool - Motley Fool - Wed Jul 16, 6:45PM CDT
Seven of the stock market's 10 sectors finished higher today, as a second day of testimony from Federal Reserve Chairwoman Janet Yellen served to assure investors that interest rates will remain low indefinitely. With that in mind, stocks seem to be...
Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 3:30PM CDT
The U.S. Patent and Trademark Office issued a new patent to Arena Pharmaceuticals, Inc. (ARNA) for its pain candidate APD371.
Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS)
Business Wire - Wed Jul 16, 7:01AM CDT
Biogen Idec (NASDAQ:BIIB) announced today a new program with Yahoo Health to raise awareness of innovative efforts to help people with multiple sclerosis (MS) across the country. The MS Visionaries(TM) program showcases self-starters who have developed programs, tools or services to benefit the MS community. Profiles of these individuals are now featured on Yahoo Health, a new digital magazine covering modern health and wellness topics.
Hospira Upgraded to Strong Buy on Orchid Facility Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 4:00PM CDT
On Jul 12, Zacks Investment Research upgraded Hospira Inc. (HSP) to a Zacks #1 Rank (Strong Buy).
Biogen Idec Falls 2.42% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 15, 3:52PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $311.92 to a high of $321.81. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $315.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 2.42%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jul 15, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $311.92 to a high of $321.81. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $315.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CVS Caremark to Expand with Navarro Discount Pharmacy Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 2:10PM CDT
Post-acquisition, CVS Caremark (CVS) will own Navarro's 33 retail drugstore locations and a specialty pharmacy named Navarro Health Services.
Will Abbott Laboratories (ABT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 11:40AM CDT
Abbott Labs (ABT) has a Zacks Rank #3 with an Earnings ESP of 0.00%.
Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 10:00AM CDT
Peregrine Pharmaceuticals, Inc. (PPHM) reported a net loss of 6 cents per share in the fourth quarter of fiscal 2014.
Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 8:04AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise 23% on the day.
IBD Big Cap 20 Leaders Hold Up Well Despite Shaky Market
at Investor's Business Daily - Mon Jul 14, 5:56PM CDT
A rising distribution day count in the major averages and an uptrend under pressure might lead some to believe that the market is in trouble -- poised for some sort of pullback. Not so fast. The charts of many IBD Big Cap 20 names don't reflect a...
Sunesis' Pediatric Plan Accepted in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 5:45PM CDT
Sunesis Pharmaceuticals, Inc.'s (SNSS) Pediatric Investigation Plan for Qinprezo was accepted by the EMA???s Pediatric Committee for AML.
Will Johnson & Johnson (JNJ) Beat this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 3:45PM CDT
Johnson & Johnson (JNJ) is scheduled to report second quarter 2014 results before the opening bell on Jul 15.
Bruker's Inspire Mapping System Fails to Inspire Share Prices - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 2:20PM CDT
Bruker Corporation's (BRKR) Inspire is a self-optimizing pioneering scanning system that delivers 10-nanometer spatial resolution in chemical and materials property mapping.
